A new study published in JAMA Oncology has identified disparate survival outcomes across sites of care.
A study by researchers at Memorial Sloan Kettering (MSK) Cancer Center, while substantiating the usefulness of Medicare administrative data in outcomes studies, provides evidence of disparate care across hospital types. Published in JAMA Oncology, the study concluded that patients treated for cancer at hospitals exempt of the Medicare prospective payment system (PPS) had significantly better 5-year survival rates than other hospitals such as NCI-designated cancer centers, other academic teaching hospitals, and community hospitals.
The authors used national Medicare claims data from 2005 to 2009, along with Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2006 for the subset of the United States covered by the SEER program. Risk-adjusted cumulative mortality rates of patients with cancer was captured in both data sets at the hospital level. The final analysis included nearly 750,000 Medicare beneficiaries with lung, prostate, breast, colon, and other cancers. In addition to survival outcomes, the analysis tested the hypothesis that information on cancer stage may not be necessary for risk adjustment studies.
Significantly big differences in survival exist between different hospitals, the study observed; while PPS-exempt hospitals had a 53% 5-year survival rate among patients, NCI designated cancer centers hovered around 49%, other academic teaching hospitals at 46%, while community cancer centers were the lowest at 44%.
“Patients need reliable information about hospitals’ survival rates so they can make informed choices about their care,” said David Pfister, MD, chief of MSK’s Head and Neck Oncology Service and lead author of the study. “But similarly important, measuring the differences in survival rates among hospitals is a first step toward improving cancer care at every hospital across the country.”
Referring to the survival care gap, Peter Bach, MD, director of MSK’s Center for Health Policy and Outcomes indicated that these results have a big public health implication. A confirmation of their study results would make it essential to break down the data and identify the source of the care gaps, he added.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More